GNLX
Genelux CorporationHealthcare·Biotechnology
$3.05
$115M market cap
Revenue
$0.0M
Free Cash Flow
$-13.6M
Rev Growth
+0.0%
FCF Margin
-170187.5%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematolog
2-Year Price History
$2.92+28.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -8.3 | -8.4 | -7.1 | -6.1 | -7.0 | -0.9 | 26.2 | 2.5 | 32.5 | -190.5% | -- | -- |
| Act | 2025-Q4 | 0.0 | -9.8 | -9.4 | -9.3 | -6.2 | -6.6 | -0.4 | 14.6 | 1.7 | 37.2 | -692.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$3.05
Market Cap$115M
Enterprise Value$91M
P/S Ratio14341.5x
P/FCF--
EV/FCF--
FCF Margin (TTM)-170187.5%
FCF Yield-11.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-16.4M
Free Cash Flow$-13.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin-227050.0%
Net Margin-204650.0%
FCF Margin-170187.5%
CapEx % of Revenue16962.5%
SBC % of Revenue27550.0%
ROIC-441.5%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.2M
Days to Cover24.3
Change (vs Prior)+4.2%
Need at least 2 settlement dates for chart
Employees
Headcount24
Revenue / Employee$333
Gross Profit / Employee$-5,875
Cash Runway
23.1months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
14.2%(+2.0% YoY)
61 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.9%(+1.7% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.5% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| WOODWARD DIVERSIFIED CAPITAL, LLC | $5.9M | $8.55 | +$446K | +$1.8M | +0.2% | $220M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $4.1M | $2.42 | +$4.1M | +$4.1M | — | $4.04T |
| Bleichroeder LP | $3.3M | $2.56 | +$1.6M | +$1.6M | -2.8% | $579M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.1M | $16.40 | +$175K | +$340K | +2.3% | $1.61T |
| BlackRock, Inc.Passive | $982K | $2.63 | +$50K | +$136K | -0.2% | $5.69T |
| BANK OF AMERICA CORP /DE/ | $784K | $3.66 | −$29K | −$205K | -0.1% | $1.36T |
| PUTNAM FL INVESTMENT MANAGEMENT CO | $680K | $4.04 | −$54K | +$680K | -0.2% | $6.71B |
| VANGUARD FIDUCIARY TRUST COPassive | $609K | $2.42 | +$609K | +$609K | — | $395.83B |
| CM Management, LLC | $605K | $2.42 | +$605K | +$605K | -4.4% | $120M |
| NORTHERN TRUST CORPPassive | $398K | $16.43 | +$52K | +$263K | -0.2% | $755.34B |
| Provident Wealth Management, LLC | $377K | $24.38 | +$0 | −$8K | -0.7% | $328M |
| STATE STREET CORPPassive | $353K | $17.89 | +$0 | +$111K | -0.2% | $2.89T |
| LPL Financial LLC | $336K | $8.05 | +$11K | +$126K | -0.2% | $372.65B |
| UBS Group AG | $297K | $5.06 | +$182K | +$132K | -0.3% | $562.11B |
| ADVISOR GROUP HOLDINGS, INC. | $288K | $3.10 | +$22K | +$275K | -0.3% | $67.63B |
| LifeSteps Financial, Inc. | $288K | $10.15 | +$2K | +$81K | -0.3% | $158M |
| MORGAN STANLEY | $213K | $9.08 | −$10K | +$46K | -0.3% | $1.65T |
| AMG National Trust Bank | $182K | $17.01 | +$0 | +$0 | -0.2% | $4.60B |
| Falcon Wealth Planning | $153K | $7.62 | +$0 | +$124K | +0.3% | $1.47B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $150K | $3.31 | −$374K | −$231K | -0.6% | $77.14B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.06%
avg per quarter
Holders (ex-self)
-0.78%
excl. this stock
Buyers (this Q)
-2.90%
14 buyers · $0.01B in
Sellers (this Q)
-0.49%
16 sellers · $0.00B out
alpha coverage: 80% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+8.7%
how holders react when this stock falls
On quiet Qs
+0.5%
−10% to +10% baseline
On rallies (+10%+)
-21.1%
how they react when this stock rises
Holders' portfolio flow this Q
+528.3%
inflows — adds are organic
Sellers' portfolio flow this Q
+1812.6%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-0.4%
Holder mid (any stock)
-0.6%
Holder rally (any stock)
-3.1%
Biggest decreases this quarter
Alyeska Investment Group, L.P.exited−$1.2MMARSHALL WACE, LLPexited−$607KMILLENNIUM MANAGEMENT LLCexited−$455KQube Research & Technologies Ltdexited−$405KSUSQUEHANNA INTERNATIONAL GROUP, LLP−$374Kα-0.6JANE STREET GROUP, LLCexited−$313KExodusPoint Capital Management, LPexited−$238KPoint72 Asset Management, L.P.exited−$172K683 Capital Management, LLC−$172Kα-2.2Lighthouse Investment Partners, LLCexited−$98K
New buyers this quarter
Top-5 holders · 66.2%
WOODWARD DIVERSIFIED CAPITAL, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Bleichroeder LP--
GEODE CAPITAL MANAGEMENT, LLC--
BlackRock, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
WOODWARD DIVERSIFIED CAPITAL, LLC2.1MProvident Wealth Management, LLC156KAE Wealth Management LLC—CHARLES SCHWAB INVESTMENT MANAGEMENT INC25KBleichroeder LP1.4MARMISTICE CAPITAL, LLC—MILLENNIUM MANAGEMENT LLC—BANK OF AMERICA CORP /DE/324KPUTNAM FL INVESTMENT MANAGEMENT CO281KBank of New York Mellon Corp—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (3 analysts)$17.3346820.0%
Current Price$3.05
Analyst Ratings
2
1
Buy: 2Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$212K
21 txns · 5 insiders · 57,669 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | SELL | Cappello Joseph | officer: Chief Technical Officer | 605 | $2.97 | $2K | $460K |
| 2026-05-11 | SELL | Smalling Ralph | officer: Head of Regulatory | 270 | $2.98 | $804 | $202K |
| 2026-05-11 | SELL | Yu Yong | officer: Chief Scientific Officer | 605 | $2.97 | $2K | $445K |
| 2026-05-11 | SELL | Zindrick Thomas | officer: President and CEO | 2,798 | $2.94 | $8K | $1.56M |
| 2026-03-25 | SELL | Smalling Ralph | officer: Head of Regulatory | 240 | $2.51 | $602 | $171K |
| 2026-03-24 | SELL | Cappello Joseph | officer: Chief Technical Officer | 906 | $2.42 | $2K | $375K |
| 2026-03-24 | SELL | Smalling Ralph | officer: Head of Regulatory | 345 | $2.42 | $835 | $165K |
| 2026-03-24 | SELL | Yu Yong | officer: SVP, Clinical Development | 906 | $2.42 | $2K | $351K |
| 2026-03-24 | SELL | Zindrick Thomas | officer: President and CEO | 3,582 | $2.42 | $9K | $1.29M |
| 2026-03-02 | SELL | Thomas John | director | 10,000 | $2.90 | $29K | $1.40M |
| 2025-12-05 | SELL | Smalling Ralph | officer: Head of Regulatory | 165 | $4.69 | $774 | $322K |
| 2025-12-01 | SELL | Thomas John | director | 10,000 | $5.00 | $50K | $2.46M |
| 2025-11-17 | SELL | Cappello Joseph | officer: Chief Technical Officer | 973 | $5.37 | $5K | $838K |
| 2025-11-17 | SELL | Smalling Ralph | officer: Head of Regulatory | 343 | $5.37 | $2K | $370K |
| 2025-11-17 | SELL | Yu Yong | officer: SVP, Clinical Development | 973 | $5.37 | $5K | $783K |
| 2025-11-17 | SELL | Zindrick Thomas | officer: President and CEO | 4,509 | $5.37 | $24K | $2.89M |
| 2025-09-03 | SELL | Smalling Ralph | officer: Head of Regulatory | 580 | $3.36 | $2K | $232K |
| 2025-08-21 | SELL | Cappello Joseph | officer: Chief Technical Officer | 2,733 | $3.34 | $9K | $525K |
| 2025-08-21 | SELL | Smalling Ralph | officer: Head of Regulatory | 1,244 | $3.36 | $4K | $234K |
| 2025-08-21 | SELL | Yu Yong | officer: SVP, Clinical Development | 3,219 | $3.36 | $11K | $493K |
Order Flow (FINRA, ~3w lag)
27.2%retail-7.3pp
16.7%dark+1.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Genelux Corporation: Repricing options while burning through cash toward a going-concern wall.
Overall Risk
9/10
Fraud
4/10
Dilution
8/10
Insolvency
9/10
Earnings Overstated
3/10
Hidden Liabilities
5/10
Legal
3/10
Audit Warnings
10/10
Hidden Upside
2/10
Contextually Acceptable
3/10